Elbasvir - Merck & Co
Alternative Names: MK-8742Latest Information Update: 27 Sep 2021
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Amides; Antivirals; Benzoxazines; Carbamates; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Pyrrolidines
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 27 Sep 2021 No development reported - Phase-II for Hepatitis C (Combination therapy) in Germany, Australia, Canada, Israel, Switzerland, New Zealand, United Kingdom (PO) (NCT02332720)
- 27 Sep 2021 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Spain, Denmark, Sweden, USA, Italy, Puerto Rico, Lithuania, France, Poland, Australia, Austria, Canada, Germany, Israel, New Zealand, United Kingdom (PO) (NCT02332707)
- 05 Oct 2017 Nippon Medical School Chiba Hokusoh Hospital plans a clinical trial for Hepatitis C (Combination therapy) in Japan (UMIN000029262)